Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma

被引：10
作者：
Steineck, Angela [1 ]
Krumm, Niklas [2 ]
Sarthy, Jay F. [1 ,3 ]
Pritchard, Colin C. [2 ]
Chapman, Teresa [2 ]
Stacey, Andrew W. [2 ]
Vitanza, Nicholas A. [1 ,3 ]
Cole, Bonnie [1 ,4 ]
机构：
[1] Seattle Childrens Hosp, Seattle, WA 98105 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[4] Univ Washington, Sch Med, Seattle, WA USA
来源：
JCO PRECISION ONCOLOGY | 2019年 / 3卷
关键词：
PHASE-II; SENSITIVITY; CETUXIMAB; PLATINUM; REPAIR;
D O I：
10.1200/PO.19.00028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 6
页数：6
相关论文
共 27 条
  • [1] Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
    Adra, N.
    Einhorn, L. H.
    Althouse, S. K.
    Ammakkanavar, N. R.
    Musapatika, D.
    Albany, C.
    Vaughn, D.
    Hanna, N. H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (01) : 209 - 214
  • [2] [Anonymous], GENEREVIEWS
  • [3] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    Bauml, Joshua
    Seiwert, Tanguy Y.
    Pfister, David G.
    Worden, Francis
    Liu, Stephen V.
    Gilbert, Jill
    Saba, Nabil F.
    Weiss, Jared
    Wirth, Lori
    Sukari, Ammar
    Kang, Hyunseok
    Gibson, Michael K.
    Massarelli, Erminia
    Powell, Steven
    Meister, Amy
    Shu, Xinxin
    Cheng, Jonathan D.
    Haddad, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1542 - +
  • [4] MutationalPatterns: comprehensive genome-wide analysis of mutational processes
    Blokzijl, Francis
    Janssen, Roel
    van Boxtel, Ruben
    Cuppen, Edwin
    [J]. GENOME MEDICINE, 2018, 10
  • [5] Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair
    Bradford, Porcia T.
    Goldstein, Alisa M.
    Tamura, Deborah
    Khan, Sikandar G.
    Ueda, Takahiro
    Boyle, Jennifer
    Oh, Kyu-Seon
    Imoto, Kyoko
    Inui, Hiroki
    Moriwaki, Shin-Ichi
    Emmert, Steffen
    Pike, Kristen M.
    Raziuddin, Arati
    Plona, Teri M.
    DiGiovanna, John J.
    Tucker, Margaret A.
    Kraemer, Kenneth H.
    [J]. JOURNAL OF MEDICAL GENETICS, 2011, 48 (03) : 168 - 176
  • [6] Dramatic response to nivolumab in xeroderma pigmentosum skin tumor
    Chambon, Fanny
    Osdoit, Sophie
    Bagny, Kelly
    Moro, Anne
    Nguyen, Jacqueline
    Reguerre, Yves
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 (02)
  • [7] A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor
    Chang, Anne Lynn S.
    Kim, Jinah
    Luciano, Richard
    Sullivan-Chang, Loretta
    Colevas, Alexander D.
    [J]. JAMA DERMATOLOGY, 2016, 152 (01) : 106 - 108
  • [8] Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature
    Deinlein, Teresa
    Lax, Sigurd F.
    Schwarz, Thomas
    Giuffrida, Roberta
    Schmid-Zalaudek, Karin
    Zalaudek, Iris
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 83 : 99 - 102
  • [9] Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
    Falchook, Gerald S.
    Leidner, Rom
    Stankevich, Elizabeth
    Piening, Brian
    Bifulco, Carlo
    Lowy, Israel
    Fury, Matthew G.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [10] Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53
    Ford, JM
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 577 (1-2) : 195 - 202
123